Progress in the development of immunotherapy for the treatment of patients with cancer

Journal of Internal Medicine

Volumn 250, Issue 6, 2001, Pages 462-475

  Rosenberg, S A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antigens; Cancer; Immunotherapy; Interleukin 2; Melanoma

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN RECOGNIZED BY T LYMPHOCYTE 1; MONOPHENOL MONOOXYGENASE; PEPTIDE; RECOMBINANT DNA; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL TRANSFER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; GENETIC CODE; HUMAN; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; VIRUS RECOMBINANT;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS;

EID: 0035665036     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00911.x     Document Type: Conference Paper

References (69)

1. Selective in vitro growth of T-lymphocytes from normal bone marrow
2. In vitro growth of murine T-cells. II. Growth of in vitro sensitized cells cytotoxic for alloantigens
3. In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens
4. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor (TCGF)
5. The lymphokine activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
6. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high dose recombinant IL-2
7. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
8. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone
9. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: Responses, treatment related morbidity and histologic findings
10. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2
11. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose proleukin interleukin-2 therapy
12. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
13. Unique murine tumor associated antigens identified by tumor infiltrating lymphocytes
14. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
15. In vivo antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2
16. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma
17. Autologous tumor-specific cytotoxic T-lymphocytes in the infiltrate of human metastatic melanomas: Activation by interleukin-2 and autologous tumor cells and involvement of the T-cell receptor
18. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas
19. Immunotherapy of patients with advanced cancer using tumor infiltrating lymphocytes and recombinant interleukin-2: A pilot study
20. Use of tumor infiltrating lymphocytes and interleukin-2 in the immuno-therapy of patients with metastatic melanoma Preliminary report
21. Tumor antigens recognized by T-cells
22. A new era for cancer immunotherapy based on the genes that encode cancer antigens
23. A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma
24. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection
25. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T-cells infiltrating into tumor
26. Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy
27. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immuno-therapy
28. A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes
29. Association of the APC tumor suppressor protein with catenins
30. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes
31. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T-lymphocytes
32. A breast and melanoma-shared tumor antigenic peptides translated from different open reading frames
33. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
34. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen
35. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen
36. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T-cells
37. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
38. A breast and melanoma-shared tumor antigen: T-cell responses to antigenic peptides translated from different open reading frames
39. Localization of Epstein-Bar virus cytotoxic T-cell epitopes using recombinant vaccinia: Implications for vaccine development
40. The class I-restricted cytotoxic T-lymphocyte response to predetermined epitopes in the hepatitis B and C viruses
41. Role of HLA-A motifs in identification of potential CTL epitopes in human papilloma virus type 16, E6 and E7 proteins
42. Generation of stable CD4+ and CD8+ T-cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations
43. Targeting p53 as a general tumor antigen
44. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes
45. Cytotoxic T-cell immunity against telomerase reverse transcriptase in humans
46. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
47. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma
48. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
49. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A* 0210 binding residues
50. Increased vaccine-specific T-cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
51. Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the elispot assay
52. Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination
53. Cancer immunology
54. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
55. Antitu-mor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response
56. T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes
57. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor infiltrating T-lymphocytes associated with in vivo tumor regression
58. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes
59. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T-lymphocytes
60. Use of an in vitro immunoselected tumor line to identify shared melanoma antigens recognized by HLA-A*0201-restricted T-cells
61. + T-cells
62. Identification of CD4+ T-cell epitopes from NY-ESO-1 presented by HLA-DR molecules
63. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice
64. Cutting edge: Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma
65. Identification of an immunodominant peptide of HER-2/neu proto-oncogene recognized by ovarian tumor-specific cytotoxic T-lymphocytes lines
66. The HER-2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T-lymphocytes
67. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells
68. Induction of human leukocyte antigen-A26-restricted and tumor-specific cytotoxic T-lymphocytes by a single peptide of the SART1 antigen in patients with cancer with different A26 subtypes
69. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies?